RPG Life Sciences Ltd

RPG Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

RPG Life Sciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its quality rating downgraded from 'Good' to 'Average' as of 16 January 2026, prompting a shift in its Mojo Grade from Hold to Sell. This change reflects a nuanced deterioration in several fundamental business parameters, despite the company’s strong historical returns and robust capital efficiency metrics.

RPG Life Sciences Ltd experienced a significant intraday decline on 28 Jan 2026, touching a low of Rs 1,912.7, reflecting an 8.88% drop from previous levels. The stock underperformed its sector and broader market indices, continuing a three-day losing streak amid persistent selling pressure and subdued market sentiment.

RPG Life Sciences Limited reported a sharp decline in profitability for the third quarter of FY2026, with net profit tumbling 39.95% quarter-on-quarter to ₹22.13 crores, down from ₹36.85 crores in Q2 FY26. The Mumbai-based pharmaceutical company, with a market capitalisation of ₹3,483 crores, witnessed its stock decline 2.16% to ₹2,089.30 following the results announcement, reflecting investor concerns over deteriorating margins and sequential profit compression despite stable revenue performance.

RPG Life Sciences Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by deteriorating technical indicators and valuation pressures despite solid financial performance. The company’s quality metrics remain strong, but concerns over long-term growth and bearish market signals have prompted a reassessment of its outlook.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a bearish stance as of mid-January 2026. This change is underscored by a downgrade in its Mojo Grade from Hold to Sell, reflecting growing concerns among market participants about the stock’s near-term trajectory despite its strong long-term returns relative to the Sensex.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend as of early 2026. Despite a recent downgrade in its technical grade from Sell to Hold, the stock exhibits a complex interplay of bullish and bearish signals across key indicators such as MACD, RSI, and moving averages, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 June 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest day decline of 0.27%, the stock’s recent technical signals suggest a cautious outlook amid mixed momentum cues from MACD, RSI, and moving averages.

RPG Life Sciences Ltd has recently exhibited a shift in price momentum, transitioning from a sideways trend to a mildly bullish stance. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s performance and underlying fundamentals suggest cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more sideways trend, reflecting a complex interplay of indicator signals. Despite a recent downgrade from a Sell to a Hold rating by MarketsMOJO on 12 June 2025, the stock’s long-term performance remains robust, though short-term price action suggests caution for investors navigating the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company's performance and outlook.

RPG LifeScience has experienced a revision in its market evaluation, reflecting changes in key analytical parameters including quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of steady operational metrics and evolving market sentiment within the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by a combination of mixed signals from key technical indicators such as MACD, RSI, moving averages, and Bollinger Bands, reflecting a nuanced market assessment for the pharmaceutical and biotechnology company.

RPG Life Sciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. While the stock’s price movement shows signs of stabilisation, key technical indicators present a nuanced picture of the pharmaceutical company’s near-term outlook.